Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.

TitleBroad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.
Publication TypeJournal Article
Year of Publication2014
AuthorsHuang J, Kang BH, Pancera M, Lee J H, Tong T, Feng Y, Imamichi H, Georgiev IS, Chuang G-Y, Druz A, Doria-Rose NA, Laub L, Sliepen K, van Gils MJ, de la Peña ATorrents, Derking R, Klasse P-J, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M
JournalNature
Volume515
Issue7525
Pagination138-42
Date Published11/06/2014
ISSN1476-4687
KeywordsAIDS Vaccines, Antibodies, Monoclonal, Antibodies, Neutralizing, Antibody Affinity, Antibody Specificity, Antigens, CD4, Cell Line, Cell Membrane, Conserved Sequence, Epitope Mapping, Epitopes, HIV Antibodies, HIV Envelope Protein gp120, HIV Envelope Protein gp41, HIV-1, Humans, Immunoglobulin Fab Fragments, Inhibitory Concentration 50, Leukocytes, Mononuclear, Models, Molecular, Molecular Sequence Data, Receptors, CCR5, Virus Internalization
Abstract

The isolation of human monoclonal antibodies is providing important insights into the specificities that underlie broad neutralization of HIV-1 (reviewed in ref. 1). Here we report a broad and extremely potent HIV-specific monoclonal antibody, termed 35O22, which binds a novel HIV-1 envelope glycoprotein (Env) epitope. 35O22 neutralized 62% of 181 pseudoviruses with a half-maximum inhibitory concentration (IC50) <50 μg ml(-1). The median IC50 of neutralized viruses was 0.033 μg ml(-1), among the most potent thus far described. 35O22 did not bind monomeric forms of Env tested, but did bind the trimeric BG505 SOSIP.664. Mutagenesis and a reconstruction by negative-stain electron microscopy of the Fab in complex with trimer revealed that it bound to a conserved epitope, which stretched across gp120 and gp41. The specificity of 35O22 represents a novel site of vulnerability on HIV Env, which serum analysis indicates to be commonly elicited by natural infection. Binding to this new site of vulnerability may thus be an important complement to current monoclonal-antibody-based approaches to immunotherapies, prophylaxis and vaccine design.

DOI10.1038/nature13601
Alternate JournalNature
PubMed ID25186731
PubMed Central IDPMC4224615
Grant ListAI84714 / AI / NIAID NIH HHS / United States
AI93278 / AI / NIAID NIH HHS / United States
P01 AI082362 / AI / NIAID NIH HHS / United States
R01 AI100790 / AI / NIAID NIH HHS / United States
UM1 AI100645 / AI / NIAID NIH HHS / United States
UM1 AI100663 / AI / NIAID NIH HHS / United States
ZIA AI000855-15 / / Intramural NIH HHS / United States
ZIA AI001090-05 / / Intramural NIH HHS / United States
CHAVI-ID: 
1
Cover Picture: